Natural killer cells as potential tools in melanoma metastatic spread control

Oncology Research

Volumn 11, Issue 8, 1999, Pages 339-343

  Nasca, Roberto ^a   Carbone, Ennio ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CD40; Cytotoxicity; Killer inhibitory receptor; Melanoma; Mhc class i; Natural killer cells

Indexed keywords

CD40 ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA G ANTIGEN; HLA-G ANTIGEN; IMMUNOGLOBULIN RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR;

ANIMAL; CANCER INVASION; GENETICS; HUMAN; MELANOMA; METABOLISM; METASTASIS; MOUSE; NATURAL KILLER CELL; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIGENS, CD40; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; MELANOMA; MICE; NEOPLASM INVASIVENESS; RECEPTORS, IMMUNOLOGIC;

EID: 0033291991     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Höglund, P.; Öhlen, C.; Carbone, E.; Franksson, L.\ Ljunggren, H-G.; Latour, A.; Koller, B.; Karre, K. Recognition of β2-microglobulin negative (β;m) T-cell blasts by natural killer cells from normal but not from β:m-mice: Nonresponsiveness controlled by β-m-bone marrow in chimeric mice. Proc. Natl. Acad. Sci. USA 88:10332-10337; 1991.
2. Kos, F. S.; Engleman, E. G. Immune regulation: A critical link between NK cells and CTLs. Immunol. Today 174:174-176; 1996.
3. Medzhitov, R.; Janeway, C. A., Jr. Innate immunity: Impact on the adaptive immune response. Curr. Opin. Immunol. 9:4-9; 1997.
4. Trinchieri, G. Biology of NK cells. Adv. Immunol. 47:187-376; 1989.
5. Bancroft, G. J. The role of natural killer cells in innate resistance to infection. Curr. Opin. Immunol. 5:503-510; 1993.
6. Bancroft, G. J.; Schreiher, R. D.; Unanue, E. R. Natural immunity a T cell independent pathway of macrophage activation, defined in the SCID mouse. Immunol. Rev. 124:5-24; 1991.
7. MacKie.R. M. Incidence, risk factors and prevention of melanoma. Eur. J. Cancer 2:S3-6; 1998.
8. MacKie, R. M.; DuPont, G. Melanoma and other skin neoplasm. Curr. Opin. Oncol. 6:177-181; 1994.
9. Van der Bruggen, P.; Traversari, C.; Chômez, P.; Lurquin, C.; de Plaen, E.; Van den Eynde, B.; Knuth, A.; Boon, T. A. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1645; 1991.
10. Kawakami, Y.; Eliyahu, S.; Delgado, C.; Robbins, P.; Rivoltini, L.; Topalian, S.; Miki, T.; Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognised by autologous T cells infiltrating into tumour. Proc. Natl. Acad. Sci. USA 91:3515-3519; 1994.
11. Salazar-Onfray, F.; Nakazawa, T.; Chhajlani, V.; Petersson, M.; Karre, K.; Masucci, G.; Celis, E.; Seite, A.; Southwood, S.; Ap-pella, E.; Kiessling, R. 1997 Synthetic peptides derived from the melanocyte stimulating hormone receptor MCI R can stimulate HLA-A2 restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma. Cancer Res. 57: 4348-4355; 1997.
12. Garrido, F.; Ruiz-Cabello, F.; Cabrera, T.; Peres-Villar, J. J.; Lopez-Botet, M.; Duggan-Keen, M.; Stem, P. L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18:89-95; 1997.
13. Femme, S.; Marincola, F. M. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16:487-489; 1995.
14. D'Urso, C. M.; Wang, Z.; Cao, Y.; Tatake, R.; Zeff, R. A.; Ferrone, S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Invest. 87:284-292; 1991.
15. Marincola, F. M.; Shamamian, P.; Alexander, R. B.; Gnarra, J. R.; Turetskaya, R. L.; Nedospasov, S. A.; Simonis, T. B.; Taubenberger, J. K.; Yannelli, J.; Mixon, A.; Restifo, N. P.; Herlyn, M.; Rosenberg, S. A. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol. 153:1225-1237; 1994.
16. Sensi, M.; Salvi, S.; Castelli, C.; Maccalli, C.; Mazzocchi, A.; Mortarini, R.; Nicolini, G.; Herlyn, M.; Parmiani, G.; Anichini, A. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: Tumor-infiltrating lymphocytes overexpress in vivo the TCR b chain sequence used by an HLA-A2 restricted and melanocyte lineage specific CTL clone. J. Exp. Med. 178:1231-1246; 1993. v
17. Ljunggren, H. G.; Karre, K. In search of the ''missing self: MHC molecules and NK cell recognition. Iromunol. Today 11:237-244; 1990.
18. Karre, K.; Ljunggren, H. G.; Piotek, G.; Kiessling/R. Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675-678; 1986.
19. Moretta, A.; Bottino, C.; Vitale, M.; Çende, D.; Biassoni, R..; Mingäri, M. C.; Moretta, L. Receptors fo'r HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14:619-648; 1996.
20. Lanier, L. L. NK cell receptors. Annu. Rev. Immunol. 16:359369; 1998.
21. Brown, M. G.; Scalzo, A. A.; Matsumoto, K.; Yokoyama, W. M. The natural killer gene complex: A genetic basis for understanding natural killer cell function and innate immunity. Immunol. Rev. . 155:53-65; 1997.
22. Lopez-Botet, M.; Pcrez-Villar, J. J.; Carretero, M.; Rodriguez, A.; Melero, I.; Bellon, T.; Llano, M.; Navarro, F. Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immunol. Rev. 155:165-174; 1997.
23. Brooks, A. G.; Posch, P. E.; Scorzelli, C. J.; Borrego, F.; Coligan, J. E. NKG2A complexed with CD94 defines a novel inhibitory natural killer receptor. J. Exp. Med. 185:795-800; 1997.
24. Braud, V. M.; Allan, D. S. J.; O'Callaghan, C. A.; Söderstrom, K.; Ddndrea, A.; Ogg, G. S.; Lazetic, S.; Young, N. T.; Bell, J. I.; Phillips,.J. H.; Lanier, L. L.; McMichael, A. J. HLA-E binds to natural killer cell receptors CD94/NKG2A, B, and C. Nature 391: 795-799; 1998.
25. Sino, A.; Sivori, S.; Bottino, C.; Malaspina, A.; Morelli, L.; Moretta, L.; Biassoni, R.; Moretta, A. Molecular cloning of NKp46: A novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 188:953-960; 1998.
26. Leibson, J. Signal transduction during natural killer cell activation: Inside the mind of a killer. Immunity 6:655-661; 1997.
27. Mason, L. H.; Anderson, S. K.; Yokoyama, W. M.; Smith, H. R.; Winkler-Pickett, R.; Ortaldo, J. R. The Ly-49D receptor activates murine natural killer cells. J. Exp. Med. 184:2119-2128; 1996.
28. Houchins, J. P.; Lanier, L. L.; Niemi, E. C.; Phillips, J. H.; Ryan, . J. C. Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C. J. Immunol. 158:3603-3609; 1997.
29. Moretta, A.; Sivori, S.; Vitale, M.; Pende, D.; Moreili, L.; Augugliaro, R.; Bottino, C.; Moretta, L. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human.natural killer cells. J. Exp. Med. 182:875-884; J995.
30. Carbone, E.; Ruggiero, G.; Terrazzano, G.; Palomba, C.; Manzo, C.; Fontana, S.; Spits, H;; Karre, Kr, Zappacosta, S. A new. mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction. J. Exp. Med. 185:2053-2060; 1997.
31. Chambers, B. J.; Salcedo, M.; Ljunggrcn, H-G: Triggering of natural killer cells by the costimulatory molecule CD80 (B7.1). Immunity 5:311-316; 1996.
32. Geldhof, A.; Moser, M.; Laspaghard, L.; Thielemans, K.; De Baetselier, P. Interleukin 12 activated natural killer cells recognise B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 91:196-206; 1998.
33. Porgador, A.; Mandelboim, O.; Restifo, N. P.; Strominger, J. L. Natural killer cell lines kill autologous b2-microglobulin deficient melanoma cells: Implications for cancer immunotherapy. Proc, Natl. Acad. Sci. USA-94:13140-13145; 1997.
34. Pende, D.; Accame, L.; Pareti, L.; Mazzocchi, A.; Moretta, A.; Parmiani, G.; Moretta, L. The susceptibility to NK cell mediated lysis of HLA class I positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur. J. Immunol. 28:2384-2394; 1998.
35. Bakker, A. B.; Phillips, J. II.; Figdor, C. G.; Lanier, L. L. Killer cell inhibitory receptors for.MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J. Immunol. 160:5239-5245; 1998N-
36. Ikeda, H.; Lethe, B.; Lehmann, F.; van Baren,- N.; Baurain, J. F.; de Smet, C.; Chambost, H.; Vitale, M.; Moretta, A.; Boon, T.; Coulie, P. G. Characterization of an antigen that is recognized oii a melanoma showing partial HLA loss by CTL expressing an NK inhibitory'receptor. Immunity 6:199-208; 1997.
37. Yahnclli, J. R.; Hyatt, C.; McConnell, S.; Hines, K.; Jacknin, L.; . Parker, L.; Sanders, M.; Roscnberg, S. A. Growth of tumor-infiltrating Jymphocytes from human solid cancers: Summary of a 5year experience. Int. J. Cancer 65:413-421; 1996. . ' '"
38. 'Gorclik, E.; Wiltrbut, R. H.I Okumura, K.; HabuYS.; Herb'erman, R. B. Role, of NK cells, in-the control of metastatic spread and growth of tumor cells in mice. Int. J. Cancer 30:107-112; 1982.
39. King, A.; Loke Y. W.; Chaouat, G. NK cells and reproduction. Immunol. Today 18:64-66;" 1997. ' . ...
40. Carosclla, E. !>.; Dausset, J.; Kirszenbaum, M. HLA'-G revisited. Immunol. Today 17:407-409; 1996
41. Rouas-Freiss, N.; Marchal-Bras Goncalves, R1.; Menier, C.; Dausset, J.; Carosella, E..D. The alphal-4 domain of HLA-G1 and HLAG2 inhibits cytotoxicity induced by natural killer cells: Is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc. Natl. Acad. Sci. USA 94:11520-11525; 1997.
42. Paul, P.; Rouas-Freiss, N.; Khalil-Daher, I.; Moreau, P.; Riteau, B.; Le Gal, F. A.; Avril, M. F.; Dausset, J.; Guillet, J. G.; Carosella, E. D. HLA-G expression in melanoma: A way for. tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA 95:4510-45J5; 1998.
43. Ponte, M.; Cantoni, C.;'Biassoni, R:\ Tradori-Cappai, A.; Bèntîvoglio. G.; Vitale, C.; Bertonc, S.; Moretta, A.; Moretta, L.; Mingari, M. C. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: Decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire: p49, an HLA-G 1-specific rece'p-' 'tor. Proc. Natl. Acad. Sci. USA 96:5674-5679; 1999.
44. Smith, C. A.; Farrah, T.; Goodwin, R, G.The TNF receptor superfamily of cellular and viral proteins:-Activation, co-stimulation, and death. Cell 76:959-962; 1994. .'
45. Ridge, J. P.; Di Rosa, F.; Matzinger, P. A conditioned dendritic' cell can be a temporal bridge between a CD4 T-helper and a Tkiller cell. Nature 393:474-478; 1998. ''"
46. Banchereau, J.; Bazan, F.; Blanchard, D.; Briere, F.; GaIizzi,-;J. P.; van Kooten, C.; Liu, Y. J.; Roussel, S.; Sealand, S. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12:881-992; 1994. '
47. Grewal, I. S.; Haveil/R.'A, CD40 and CD154 in cell mediated immunity. Annu. Rev. Immunol. 16:111-135; 1998
48. Carbone, E.; Terrazzano, G.; .Ruggiero, G.; Zanzi, D.; Ottaianb;A.; Manzo, C.; Karre; K.; Zappacosta, S. Recognition of autologous dendritic cells by human NK cells. Eur. J. Immunol. 29: 4022-4029; 1999. ' . '
49. Thomas, W. D.;-Smith, M. J.; Si; Z., Hersey, P. Expression of the co-stimulatory molecule CD40 on melanoma cells. -Int. J. Cancer 68:795-801; 1996.
50. van den Oord, J. J.; Macs, A.; Slas, M.; Nuyts, J.; Battocchio, S.; Kasran, A.; Garmyn, M.; De Wever, I.; De Wolf-Peeters, C. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am. J. Pathol. 149:1953-1961; 1996.
51. von Leoprechting, A.; van der Bruggen, P.; Pahl, H. L.; Aruffo, A.; Simon, J. C. Stimulation of CD40 on immunogenic human melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 59:1287-1294; 1999.
52. Martin-Fontecha, A.; Assarsson, E.; Carbone, E.; Karre, K.; l.junggren, H-G. Triggering of murine NK cells by CD40 and CD86 (B7.2). J. Immunol. 162:5910-5916; 1999.
53. Allavena, P.; Peccatori, F.; Maggioni, D.; Pirovano, P.; Mantovani, A. Killing of tumor cells with pleiotropic drug resistance by OK432-activated effector cells. Immunopharmacol. Immunotoxicol. 11:257-268; 1989.
54. Cohen, P. J.; Lotzc, M. T.; Roberts, J. R.; Rosenberg, S. A.; Jaffe, E. S. The immunopathology of sequential tumor biopsies in patients treated with interIeukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am. J. Pathol. 129(2): 208-216; 1987.
55. Dillman, R. O.; Church, C.; Oldham, R. K.; West, W. H.; Schwartzberg, L.; Birch, R. In patient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 71:2358-2370; 1993.
56. Rosenberg, S. A.; Lotze, M. T.; Yang, J. C.; Topalian, S. L.; Chang, A. E.; Schwartzentruber, D. J.; Aebersold, P.; Leitman, S.; Linehan, W. M.; Seipp, C. A. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with iymphokineactivated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85:622-632; 1993.